Tesamorelin vs MOTS-c: Visceral Fat, Energy, Evidence, Prices, and COA Checks
Tesamorelin has the stronger human evidence for reducing visceral fat, while MOTS-c sits in the experimental mitochondrial-energy and metabolic research lane. Compare evidence maturity, current price per milligram, and lot-level COA proof before choosing.
Short Answer: Tesamorelin for Human Visceral-Fat Evidence, MOTS-c for Experimental Metabolic Research
Tesamorelin is the evidence-led choice for visceral abdominal fat because randomized human trials measured that outcome. MOTS-c is the experimental choice for mitochondrial signaling, AMPK, energy metabolism, and exercise adaptation.
They are not substitutes. Tesamorelin is a 44-amino-acid growth hormone-releasing hormone analog that stimulates pituitary GH release and downstream IGF-1. MOTS-c is a 16-amino-acid mitochondrial-derived peptide encoded within mitochondrial DNA.
No head-to-head trial compares them, and no controlled human study shows that combining them improves outcomes.
Tesamorelin vs MOTS-c at a Glance
| Factor | Tesamorelin | MOTS-c |
|---|---|---|
| Primary lane | Visceral fat and GH-axis body composition | Mitochondrial and metabolic research |
| Mechanism | GHRH, GH, IGF-1 | Mitochondrial signaling, AMPK |
| Evidence | Randomized human outcomes | Mainly cells and mice |
| Strongest human signal | CT-measured VAT reduction | Natural exercise response in 10 men |
| Low-end list price | $3.85 per labeled mg | About $1.38 per labeled mg |
The evidence is not equal. Compare live tesamorelin prices and MOTS-c prices within each compound, never by treating their milligrams as equivalent.
What the Tesamorelin Human Data Actually Show
Tesamorelin’s visceral-fat case rests on two randomized, placebo-controlled Phase 3 trials totaling roughly 800 adults with HIV-associated abdominal fat accumulation. Pooled results showed about a 15% to 18% reduction in CT-measured visceral adipose tissue at 26 weeks. That reduction was largely sustained to 52 weeks among participants who continued treatment.
A separate six-month randomized trial makes the distribution effect clearer. Visceral adipose tissue changed by about -34 cm² with tesamorelin versus +8 cm² with placebo, for a -42 cm² treatment effect, p=0.005. Liver fat had a -2.9 percentage-point net treatment effect, p=0.003. Subcutaneous adipose tissue did not differ significantly, with a -6 cm² treatment effect, p=0.37.
That combination matters. The strongest signal is not generic scale loss. It is measured visceral-fat reduction, with no significant difference in subcutaneous fat in that trial.
An exploratory analysis looked only at tesamorelin participants who had at least an 8% VAT decrease. It compared 193 responders with 148 placebo participants after 26 weeks. Four trunk-muscle groups showed density coefficients from 1.56 to 4.86 Hounsfield units, all p<0.005. Rectus and psoas total area increased by 0.44 and 0.46 cm², also p<0.005.
Those muscle findings are interesting, but responder selection limits the conclusion. The HIV-lipodystrophy data also should not be turned into a guaranteed result for healthy adults, general abdominal fat, or bodybuilding. The advantage is evidence maturity and visceral-fat specificity.
What the MOTS-c Data Actually Show
MOTS-c was first described in 2015. Foundational cell and mouse research linked it to AMPK, skeletal-muscle glucose handling, improved insulin sensitivity, and protection against high-fat-diet obesity and insulin resistance. That creates a compelling metabolic research lane, but native MOTS-c still lacks a published controlled human intervention trial establishing fat-loss, energy, or performance outcomes.
The clearest human finding comes from a 2021 Nature Communications study of 10 healthy young men, with a mean age of 24.5 years and mean BMI of 24.1. After stationary cycling, the body’s own skeletal-muscle MOTS-c increased 11.9-fold. Circulating endogenous MOTS-c rose 1.6-fold during exercise and 1.5-fold after exercise, then returned toward baseline after four hours.
This was a study of natural MOTS-c response. Researchers did not administer MOTS-c to the men.
The same paper did administer MOTS-c to young, middle-aged, and old mice. Treated old mice ran about 2-fold longer and 2.16-fold farther. Those are useful animal signals, not a human protocol.
CB4211 adds human-adjacent context, but it is an engineered MOTS-c analog rather than native MOTS-c. Sponsor-reported Phase 1b data randomized 20 adults with obesity and NAFLD, 11 to CB4211 25 mg and 9 to placebo for four weeks. ALT changed -21% versus +4%, AST -28% versus -11%, and glucose -6% versus 0%. No serious adverse events were reported.
That trial was small, short, and based on sponsor topline reporting. It supports continued interest in the pathway, not proof that native MOTS-c produces the same outcomes.
Which Research Goal Fits Each Peptide
Choose tesamorelin for visceral abdominal fat or GH-axis body-composition research. Randomized human trials directly measured CT-derived visceral adipose tissue, making it the clearer lane for a defined human outcome.
Choose MOTS-c for experimental work on mitochondrial signaling, metabolic flexibility, exercise response, healthy aging, and skeletal-muscle energy biology. These remain research goals, not proven human outcomes for administered native MOTS-c.
For total scale weight or generic fat loss, this is not a GLP-1-style percentage-weight-loss contest. Tesamorelin’s clearest signal is fat distribution. MOTS-c offers promising mechanistic and animal data plus a human study of the body’s natural exercise response.
Do not turn the comparison into a stack recommendation. No controlled human evidence shows that combining a GH-axis peptide with MOTS-c creates additive fat-loss, energy, or performance benefits.
The decision is straightforward: tesamorelin fits a human-evidence-led visceral-fat question, while MOTS-c fits exploratory mitochondrial and metabolic research. After choosing the lane, compare prices within that compound and require current-lot proof.
Current Price and Verified-Value Comparison
Checked September 30, 2026. Prices, codes, inventory, shipping, tax, payment fees, and lots can change. Confirm the live offer before checkout.
| Compound and vendor | Listed vial | Current catalog value |
|---|---|---|
| Tesamorelin, RetaOne | 20 mg for $77 | $3.85 per labeled mg |
| Tesamorelin, NextGen | 20 mg for $90 | $4.50 per mg |
| Tesamorelin, Ascension | 5 mg for $50 | $25 with 50% PEPTIDEPUB, $5.00 per mg |
| Tesamorelin, Valor | 10 mg for $59.99 | About $53.99 with 10% off, about $5.40 per mg |
| MOTS-c, RetaOne | 40 mg for $55 | About $1.38 per labeled mg |
| MOTS-c, Puratek | 40 mg for $69.95 | About $1.75 per mg |
| MOTS-c, NextGen | 40 mg for $80 | $2.00 per mg |
| MOTS-c, Ascension | 10 mg for $62 | $31 with 50% PEPTIDEPUB, $3.10 per mg |
MOTS-c has the lower low-end price per labeled milligram in this snapshot, but that does not make it a cheaper substitute for tesamorelin. Milligrams from two different compounds are not therapeutically equivalent. Use price per milligram only to compare offers for the same compound and vial identity.
Start with the live tesamorelin listings or MOTS-c listings. Once the current lot’s measured fill is known, use the cost-per-dose calculator to normalize same-compound value. Review evidence and terms before using PeptidePub’s verified Bodybuilding Health path.
COA and Vendor Checks Before Buying
A useful COA matches the exact compound and current lot. Look for a named independent lab, measured net content, purity, identity, sterility, endotoxins, heavy metals, and contaminant screening where available. Vendor-level proof does not verify every vial.
Ascension’s tesamorelin evidence is Kovera Labs report KVR-2026-E24151 for Tesamorelin 5 mg, lot 32-05260628, dated June 2, 2026. It covers net content, purity, identity, heavy metals, sterility, and endotoxins.
Its MOTS-c evidence is Kovera report KVR-2026-B16BA6, lot 24-05260628, dated June 26, 2026. PeptidePub records 99.588% purity and 11.09 mg measured net content for the reviewed 10 mg product, plus identity, heavy-metal, sterility, and endotoxin checks.
Ascension scores six of seven fields in PeptidePub’s reviewed framework. The missing field is additional contaminant or fentanyl screening. This is strong evidence for the reviewed products and lots, not automatic proof of other inventory.
Use vendor profiles to compare testing depth and the methodology to understand each field. Match the lot before applying a discount.
Valor’s reviewed evidence is Accumark Labs report UWUE-WG2F for Tesamorelin 10 mg, lot ARC-TS10-010, dated August 25, 2026. It covers net content, purity, identity, sterility, and endotoxins. The reviewed score does not include heavy metals or contaminant screening.
Never transfer a report across compound, vendor, vial size, or lot. Before buying, check:
- Exact compound identity and current checkout lot
- Named independent laboratory
- Measured net content and purity
- Sterility and endotoxins
- Heavy metals and additional contaminant screening
- Delivered price per verified milligram after the current code
Measured fill matters because a label claim and a laboratory result can differ. Vendor testing depth is a useful filter, but it does not prove every product in stock. Open the report and compare its compound, vial size, lot number, and date with the item in the cart.
Once the lot passes, check current deals. For compound-specific buying help, use the tesamorelin buyer guide, MOTS-c buyer guide, or detailed 2026 tesamorelin cost guide.
FAQ
Is tesamorelin or MOTS-c better for visceral fat?
Tesamorelin has stronger human evidence. Randomized trials directly measured visceral adipose tissue and found about a 15% to 18% reduction at 26 weeks in adults with HIV-associated abdominal fat accumulation. MOTS-c findings remain largely preclinical.
Is MOTS-c better for energy?
It has a compelling mitochondrial and exercise-response story. Endogenous MOTS-c rose during exercise in 10 men, and administered MOTS-c improved performance in mice. No controlled human trial of native MOTS-c proves an energy or performance benefit.
Can they be combined?
No controlled human evidence shows additive benefit. Different mechanisms alone do not establish that a stack improves fat loss, energy, or performance.
Which is cheaper?
In the September 30, 2026 snapshot, low-end offers started near $1.38 per labeled mg for MOTS-c and $3.85 per labeled mg for tesamorelin. Milligrams across different compounds are not equivalent, so compare value only within the chosen peptide.
What should the COA show?
Require exact identity, matching lot, named independent lab, measured net content, and purity. Prefer sterility, endotoxins, heavy metals, and additional contaminant screening too. Another lot or compound is not proof of the vial being purchased.
Bottom Line: Buy for the Research Goal, Then Compare Proof and Price
Tesamorelin wins when the question is human-evidence-led visceral-fat research. MOTS-c wins when the question is experimental mitochondrial-energy and metabolic research. Neither is universally better.
Keep evidence maturity attached to every benefit. Tesamorelin has randomized human VAT data. MOTS-c has strong mechanistic and animal evidence plus human observational response data, but not controlled intervention outcomes for native MOTS-c.
Choose the compound that fits the research goal, then buy the current lot with the strongest combination of exact identity, measured fill, contamination testing, and same-compound price-per-milligram value. Compare tesamorelin prices or MOTS-c prices, inspect current evidence through vendor profiles, normalize value with the cost-per-dose tool, and apply current deals after the lot passes.
Related Guides
Sources
Follow @PeptidePub on X for daily peptide price drops.
Get peptide price-drop alerts
Set a target price and we'll email you when a trusted, third-party-tested vendor drops below it. No spam, unsubscribe anytime.
From the community
Ask a questionRelated Articles
Tesamorelin Cost in 2026: Price Per Mg, Vendors, Deals, and COA Checks
Tesamorelin Buyer Guide: Visceral-Fat Evidence, Prices, Deals, and COA Checks
MOTS-c Buyer Guide: Energy, Metabolic Research, COA Proof, Vendors, and Price Per Mg